Pfizer reported Q4 FY 2015 earnings of $0.53 per share (versus $0.54 in Q4 FY 2014), beating analysts' consensus of $0.52.
The company's quarterly revenues amounted to $14.047 bln (+7.1% y/y), beating consensus estimate of $13.595 bln.
Pfizer also issued guidance for FY 2016, projecting EPS of $2.20-2.30 (versus analysts' consensus of $1.98) and revenues of $49-51 bln (versus analysts' consensus of $53 bln).
PFE fell to $29.75 (-1.39%) in pre-market trading.